Top Industry Leaders in the Chordoma Disease Market
January 2024:A Phase II clinical trial evaluating the safety and efficacy of ibrutinib (Calquence) in combination with everolimus (Afinitor) for advanced Chordoma is underway at MD Anderson Cancer Center.
December 2023:A study published in the Journal of Clinical Oncology suggests that immunotherapy with pembrolizumab (Keytruda) may offer promising results in patients with advanced Chordoma.
November 2023:Researchers from the University of California San Francisco announce the identification of a new genetic mutation associated with Chordoma, potentially paving the way for targeted therapy development.
October 2023:Blue Sphere Corporation receives orphan drug designation from the FDA for its investigational drug, BLS-804, for the treatment of Chordoma.
September 2023:Sanofi partners with the Chordoma Foundation to support research and development efforts for Chordoma treatment.
August 2023:The Chordoma Foundation launches a new research initiative focused on identifying biomarkers for early diagnosis of Chordoma.
List of Chordoma Disease Key Companies in the Market
- AstraZeneca plc (U.K.)
- Amgen, Inc. (U.S.)
- Actavis plc (U.S.)
- Bristol-Myers Squibb and Company (U.S.)
- Celgene Corporation (U.S.)
- Eli Lilly and Company (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- GlaxoSmithKline plc (UK)
- Novartis International AG (Switzerland)
- Pfizer, Inc. (U.S.)
- Sanofi S.A. (France)
- Debiopharm Group (Switzerland)
- Bayer AG (Germany)
- Johnson & Johnson (U.S.)
- Merck & Co., Inc. (U.S.)
- Optivus Proton Therapy, Inc. (U.S.)
- ProCure Treatment Centers, Inc. (U.S.)
- Varian Medical Systems, Inc.(U.S.)
- Amura Holdings Ltd. (U.S.)
- Catena pharmaceuticals Inc. (U.S.)
- Celldex therapeutics Inc. (U.S.)
- Eckert & Ziegler BEBIG (Germany)
- Infinity Pharmaceuticals (U.S.)
- Medivir AB (Sweden)
- Merrion Pharmaceuticals Plc. (U.S.).
